Jpmorgan Chase & CO Fibrogen Inc Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Fibrogen Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,673,555 shares of FGEN stock, worth $1.04 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,673,555
Previous 315,361
430.68%
Holding current value
$1.04 Million
Previous $280,000
138.93%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding FGEN
# of Institutions
82Shares Held
47.2MCall Options Held
387KPut Options Held
672K-
Primecap Management CO Pasadena, CA9.91MShares$6.14 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.8MShares$4.22 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.88MShares$3.65 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.91MShares$2.42 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.41MShares$1.49 Million0.0% of portfolio
About FIBROGEN INC
- Ticker FGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,741,200
- Market Cap $58.1M
- Description
- FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...